NASDAQ:OCUL

Ocular Therapeutix Stock Insider Trading

Healthcare > Biotechnology

Buy OCUL

*Your capital is at risk

$8.35

+0.0400 (+0.481%)

At Close: Jun 03, 2026

Ocular Therapeutix Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 45.47. In total, the insiders bought 9.66M and sold 1.84M OCUL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	45.47
● Buy	9.66M shares
● Sell	1.84M shares
55% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 12, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 45.47. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 20, 2026 Buy	Common Stock	Robins Jason Shand Interim CFO	C-Suite Officer	0 Value: $0
Jan 20, 2026 Buy	Stock Option (Right to Buy) A-Award	Robins Jason Shand Interim CFO	C-Suite Officer	33 000 Value: $377.9K
Jan 02, 2026 Buy	Common Stock A-Award	Waheed Nadia Chief Medical Officer	Officer	79 112 Value: $935.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Nayak Sanjay Chief Strategy Officer	Officer	197 650 Value: $2.34M
Jan 02, 2026 Buy	Common Stock A-Award	Nayak Sanjay Chief Strategy Officer	Officer	64 900 Value: $767.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Meyers Steve Lawrence Chief Commercial Officer	Officer	197 650 Value: $2.34M
Jan 02, 2026 Buy	Common Stock A-Award	Meyers Steve Lawrence Chief Commercial Officer	Officer	64 900 Value: $767.1K
Jan 02, 2026 Buy	Common Stock A-Award	Anderman Todd Chief Legal Officer	Officer	64 900 Value: $767.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Anderman Todd Chief Legal Officer	Officer	197 650 Value: $2.34M
Jan 02, 2026 Buy	Common Stock A-Award	Kaiser Peter Chief Development Officer	Officer	79 112 Value: $935.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Kaiser Peter Chief Development Officer	Officer	240 932 Value: $2.85M
Jan 02, 2026 Buy	Common Stock A-Award	Saroj Namrata Chief Business Officer	Officer	79 112 Value: $935.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Saroj Namrata Chief Business Officer	Officer	240 932 Value: $2.85M
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Waheed Nadia Chief Medical Officer	Officer	240 932 Value: $2.85M
Jan 02, 2026 Buy	Common Stock A-Award	Heier Jeffrey S. Chief Scientific Officer	Officer	79 112 Value: $935.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Heier Jeffrey S. Chief Scientific Officer	Officer	240 932 Value: $2.85M
Jan 02, 2026 Buy	Common Stock A-Award	Notman Donald See Remarks	Officer	79 112 Value: $935.1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Notman Donald See Remarks	Officer	240 932 Value: $2.85M
Nov 26, 2025 Buy	Common Stock G-Gift	Dugel Pravin See Remarks	Officer	49 754 Value: $604.0K
Nov 26, 2025 Sell	Common Stock G-Gift	Dugel Pravin See Remarks	Officer	49 754 Value: $0
Nov 24, 2025 Sell	Common Stock S-Sale	Nayak Sanjay Chief Strategy Officer	Officer	1 878 Value: $22.6K
Nov 24, 2025 Sell	Common Stock S-Sale	Dugel Pravin See Remarks	Officer	19 530 Value: $235.1K
Nov 24, 2025 Sell	Common Stock S-Sale	Heier Jeffrey S. Chief Scientific Officer	Officer	3 469 Value: $41.8K
Nov 24, 2025 Sell	Common Stock S-Sale	Kaiser Peter Chief Development Officer	Officer	3 007 Value: $36.1K
Nov 05, 2025 Sell	Common Stock S-Sale	Saroj Namrata Chief Business Officer	Officer	25 865 Value: $277.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OCULAR THERAPEUTIX

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammati...

Read Full Profile Here